Filing Flows › Health Care › Amarin (AMRN)
Amarin (AMRN) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 28, 2026 · Amarin (AMRN) Q3 2026 earnings results →
Q3 2026 Revenue down 20% year over year to $39.5M · 1¢ of every $1 of revenue kept as net profit · operating margin -6.0%
Amarin made $39.5M in Q3 2026 (-20% Y/Y): Product $36.9M, Licensing and Royalty $2.7M. Operating margin -6.0%, net earnings $245K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 28, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $39.5M in Q3 2026, down 20% year over year and down 6% from the previous quarter. Product was the largest line at 93% of revenue. Product lost $11.7M year over year (down 24%), 115% of the total change.
Gross margin was 40.9%, down 3.8 points from Q3 2025. Operating costs exceeded revenue by $2.4M, an operating margin of -6.0%. Operating expenses fell 44% while revenue fell 20%. Net earnings were $245K. The effective tax rate was 22.2%. Non-operating items added $2.7M, 849% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $9.2M, 3764% of net earnings. Non-cash charges added back $1.4M of share-based compensation. Working capital and other items added $7.6M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 28, 2026 | $39.5M | -20% | -6.0% | $245K | $9.2M |
| Q2 2026 | 10-Q | Jul 29, 2026 | $42.2M | -42% | -28.5% | −$7.7M | $6.6M |
| Q1 2026 | 10-Q | Apr 29, 2026 | $45.1M | +7% | -25.1% | −$10.5M | $6.4M |
| Q4 2025 | 10-K | Mar 2, 2026 | $49.2M | -21% | -12.9% | −$1.2M | $15.3M |
| Q3 2025 | 10-Q | Oct 29, 2025 | $49.7M | +17% | -22.4% | −$7.7M | −$12.7M |
| Q2 2025 | 10-Q | Jul 30, 2025 | $72.7M | +8% | -22.0% | −$14.1M | $16.6M |
| Q1 2025 | 10-Q | May 7, 2025 | $42.0M | -26% | -39.9% | −$15.7M | −$12.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Amarin
Amarin is a global pharmaceutical company committed to reducing the cardiovascular disease (CVD) burden for patients and communities and to advancing the science of cardiovascular care around the world. We own and support a global branded product approved by multiple regulatory authorities based on a track record of proven efficacy and safety and backed by robust clinical trial evidence. Our commercialization model includes a direct sales approach in the U.S. and an indirect distribution strategy internationally, through a syndicate of reputable and well-established partners with significant geographic expertise, covering close to 100 markets worldwide. Our success is driven by a dedicated, talented, and highly skilled team of experts passionate about the fight against the world’s leading cause of death, CVD.
In its own words, from its 8-K, filed Jul 29, 2026.
Amarin against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -20% against the peers' median +7%. Operating margin: -6.0% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| AMRN Amarin | Q3 2026 | $39.5M | -20% | -6.0% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Amarin 10-Q on SEC EDGAR · CIK 897448 · Pharmaceutical Preparations
13F: who owns AMRN and who is buying
More on AMRN
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results